The role of lipids in the development of diabetic microvascular complications: implications for therapy

Area of Science:

• Endocrinology and Metabolism
• Cardiovascular Disease
• Nephrology

Background:

• Dyslipidemia is a primary risk factor for coronary heart disease, particularly in patients with diabetes mellitus.
• The association between dyslipidemia and microvascular complications in diabetes, and the impact of lipid-lowering therapies, remain less explored.
• Microvascular complications in diabetes include diabetic retinopathy and nephropathy.

Purpose of the Study:

• To systematically review studies on the association between dyslipidemia and microvascular disease in diabetes.
• To evaluate the effect of lipid-lowering therapy on microvascular complications in diabetic patients.
• To review potential mechanisms linking dyslipidemia to diabetic microvascular disease.

Main Methods:

• Systematic review of association and intervention studies.
• Review of proposed pathophysiological mechanisms.
• Analysis of data on lipid-lowering agents, including HMG-CoA reductase inhibitors.

Main Results:

• Dyslipidemia may contribute to or worsen diabetic retinopathy and nephropathy through various mechanisms, including endothelial damage and atherosclerosis.
• Hyperlipidemia is associated with a more rapid decline in glomerular filtration rate and increased albuminuria.
• Lipid-lowering therapy, particularly with statins, may offer significant benefits for diabetic retinopathy and nephropathy, though long-term data are limited.

Conclusions:

• Dyslipidemia is implicated in the pathogenesis of diabetic microvascular complications.
• Lipid-lowering interventions show potential for managing diabetic retinopathy and nephropathy.
• Aggressive management of diabetic dyslipidemia is recommended for both macrovascular and microvascular disease prevention, pending further long-term evidence.